NO20054216L - Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag - Google Patents

Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag

Info

Publication number
NO20054216L
NO20054216L NO20054216A NO20054216A NO20054216L NO 20054216 L NO20054216 L NO 20054216L NO 20054216 A NO20054216 A NO 20054216A NO 20054216 A NO20054216 A NO 20054216A NO 20054216 L NO20054216 L NO 20054216L
Authority
NO
Norway
Prior art keywords
dipyridamole
angiotensin
antagonist
combination
acetylsalicylic acid
Prior art date
Application number
NO20054216A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054216D0 (no
Inventor
Axel Riedel
Lutz Hilbrich
James C Gilbert
Michael Humphreys
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054216(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20054216L publication Critical patent/NO20054216L/no
Publication of NO20054216D0 publication Critical patent/NO20054216D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20054216A 2003-02-13 2005-09-12 Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag NO20054216D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (de) 2003-02-13 2003-02-13 Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP03018212 2003-08-08
PCT/EP2004/001208 WO2004071385A2 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention

Publications (2)

Publication Number Publication Date
NO20054216L true NO20054216L (no) 2005-09-12
NO20054216D0 NO20054216D0 (no) 2005-09-12

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054216A NO20054216D0 (no) 2003-02-13 2005-09-12 Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag

Country Status (29)

Country Link
US (5) US20040214802A1 (sl)
EP (2) EP1733729A1 (sl)
JP (1) JP2006517557A (sl)
KR (1) KR20050100676A (sl)
CN (1) CN1750830A (sl)
AR (1) AR043173A1 (sl)
AT (1) ATE395921T1 (sl)
AU (1) AU2004212305A1 (sl)
BR (1) BRPI0407457A (sl)
CA (1) CA2515941A1 (sl)
DE (2) DE10306179A1 (sl)
DK (1) DK1603573T3 (sl)
EA (1) EA200501231A1 (sl)
EC (1) ECSP055963A (sl)
ES (1) ES2308147T3 (sl)
HR (1) HRP20050713A2 (sl)
MX (1) MXPA05008572A (sl)
NO (1) NO20054216D0 (sl)
NZ (1) NZ542302A (sl)
PE (1) PE20050191A1 (sl)
PL (1) PL378204A1 (sl)
PT (1) PT1603573E (sl)
RS (1) RS20050618A (sl)
SI (1) SI1603573T1 (sl)
TW (1) TW200501957A (sl)
UA (1) UA83481C2 (sl)
UY (1) UY28182A1 (sl)
WO (1) WO2004071385A2 (sl)
ZA (1) ZA200505956B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
JP6925272B2 (ja) * 2015-01-28 2021-08-25 リアルイン ライフ サイエンス リミテッド ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
EP1013273A1 (en) 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
JP2002293742A (ja) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd 鎮痛・抗炎症剤
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe

Also Published As

Publication number Publication date
ES2308147T3 (es) 2008-12-01
WO2004071385A2 (en) 2004-08-26
DK1603573T3 (da) 2008-09-15
DE602004013937D1 (de) 2008-07-03
AR043173A1 (es) 2005-07-20
HRP20050713A2 (en) 2006-09-30
EP1603573B8 (en) 2009-04-01
EP1603573B1 (en) 2008-05-21
SI1603573T1 (sl) 2008-10-31
EP1603573A2 (en) 2005-12-14
CN1750830A (zh) 2006-03-22
US20060241089A1 (en) 2006-10-26
EP1733729A1 (en) 2006-12-20
KR20050100676A (ko) 2005-10-19
US20040214802A1 (en) 2004-10-28
US20070004687A1 (en) 2007-01-04
WO2004071385A3 (en) 2005-01-06
ATE395921T1 (de) 2008-06-15
PT1603573E (pt) 2008-06-26
MXPA05008572A (es) 2005-11-04
ECSP055963A (es) 2006-01-16
AU2004212305A1 (en) 2004-08-26
EA200501231A1 (ru) 2006-02-24
ZA200505956B (en) 2006-03-29
NZ542302A (en) 2008-12-24
US20080113949A1 (en) 2008-05-15
BRPI0407457A (pt) 2006-01-31
UA83481C2 (uk) 2008-07-25
DE10306179A1 (de) 2004-08-26
US20080188497A1 (en) 2008-08-07
RS20050618A (en) 2007-09-21
NO20054216D0 (no) 2005-09-12
PL378204A1 (pl) 2006-03-20
JP2006517557A (ja) 2006-07-27
CA2515941A1 (en) 2004-08-26
PE20050191A1 (es) 2005-04-12
TW200501957A (en) 2005-01-16
UY28182A1 (es) 2004-09-30

Similar Documents

Publication Publication Date Title
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
MX2007005367A (es) Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
BR0113710A (pt) Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
ECSP055525A (es) Inhibidores de cinasas de tirosina
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
NO20073802L (no) Leuprolidacetat og acetylkolinsteraseinhibitor eller NMDA-reseptorantagonister for behandlingen av Alzheimers sykdom
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
RS54185B1 (en) USE OF 24-ORDER
NO20035602D0 (no) Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
AR038858A1 (es) Combinacion
WO2007010501A3 (en) A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
GB9930075D0 (en) Medicaments
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2007145993A3 (en) Modified compositions and methods for enhancing brain function

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application